About
Antibody-based Treatments
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
448
By Phase
PHASE1: 3PHASE1/PHASE2: 3
By Status
COMPLETED: 4RECRUITING: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06143371Lead Sponsor
A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.
PHASE1Recruiting
80 participants
Started: Aug 21, 2023 · Completed: Apr 24, 2025
NCT05181462Lead Sponsor
Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.
PHASE1/PHASE2Active, not recruiting
117 participants
Started: Jan 11, 2022 · Completed: Aug 31, 2026
NCT05116891Lead Sponsor
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
PHASE1/PHASE2Completed
40 participants
Started: Sep 22, 2021 · Completed: Jun 23, 2023
NCT04990037Lead Sponsor
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
PHASE1Completed
25 participants
Started: Jul 19, 2021 · Completed: Jun 15, 2023
NCT04452214Lead Sponsor
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
PHASE1Completed
19 participants
Started: Sep 24, 2020 · Completed: Jun 28, 2023
Locations (1)
Headquarters
Lund, Sweden
Map
Loading map...